Notizie e Video - OXFORD BIOMEDICA ORD 50P - Pagina 3

Oxford BioMedica, UK Cystic Fibrosis Gene Therapy Consortium, Boehringer Ingelheim and Imperial Innovations Form Partnership to Develop a Novel Gene Therapy Treatment for Cystic Fibrosis Oxford, UK – 6 August 2018: Oxford BioMedica plc (LSE:OXB) (“Oxford BioMedica” or “the Group”), a leading gene and cell therapy group, today announces that it has entered into a process development collaboration agreement with the UK Cystic Fibrosis Gene Therapy Consortium (GTC) and Imperial...

Oxford BioMedica Announces Collaboration and Licence Agreement with Bioverativ in the Field of Haemophilia Gene Therapy PR Newswire OXFORD, England, February 15, 2018 OXFORD, England , February 15, 2018 /PRNewswire/ -- Oxford BioMedica plc (LSE:OXB) ("Oxford BioMedica" or "the Group"), a leading gene and cell therapy group, today announces that it has completed a major new collaboration & licence agreement with Bioverativ Inc. for the development and manufacturing of lentiviral vectors to treat...

Oxford BioMedica notes the sBLA submission to FDA for Kymriah(TM) in adult patients with r/r DLBCL Oxford, UK - 31 October 2017 : Oxford BioMedica plc ("Oxford BioMedica" or "the Group") (LSE:OXB), a leading gene and cell therapy group, today notes an announcement by Novartis confirming submission of a supplemental Biologics License Application (sBLA) to the US Food and Drug Administration (FDA) for Kymriah TM (tisagenlecleucel) suspension for intravenous infusion, formerly CTL019, for the...

Oxford BioMedica plc ("Oxford BioMedica" or "the Group") (LSE:OXB), a leading gene and cell therapy group, notes that the US Food and Drug Administration (FDA) has scheduled an Oncologic Drugs Advisory Committee meeting on 12 July 2017 to review the CTL019 (tisagenlecleucel-T) Biologics License Application (BLA) filing in relapsed and refractory (r/r) paediatric and young adult patients with B-cell acute lymphoblastic leukaemia (ALL). Novartis announced in March 2017 that the FDA accepted CTL019...

3 April 2016: Oxford Biomedica CEO, John Dawson, talks to IGTV about how the company plans to manage its debt and relationship with Novartis....

VIDEO FINANCIAL REPORTING Why invest in is the first financial video platform where you can easily search through thousands of videos describing global ......

...